1. Home
  2. MANE vs PGEN Comparison

MANE vs PGEN Comparison

Compare MANE & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MANE

Veradermics Incorporated Common Stock

N/A

Current Price

$47.12

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$3.58

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MANE
PGEN
Founded
2019
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
MANE
PGEN
Price
$47.12
$3.58
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.67
AVG Volume (30 Days)
259.5K
4.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$230,981,000.00
Revenue This Year
N/A
$342.78
Revenue Next Year
N/A
$478.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.26
$1.11
52 Week High
$51.56
$5.47

Technical Indicators

Market Signals
Indicator
MANE
PGEN
Relative Strength Index (RSI) 67.60 33.80
Support Level $39.73 $3.49
Resistance Level $51.56 $5.10
Average True Range (ATR) 4.05 0.36
MACD 0.04 -0.13
Stochastic Oscillator 70.52 1.57

Price Performance

Historical Comparison
MANE
PGEN

About MANE Veradermics Incorporated Common Stock

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: